IQV vs LH
IQV: IQVIA is a global leader in clinical research and healthcare data analytics that powers the development and commercialization of life-saving medical treatments. LH: Labcorp is a global leader in diagnostics and drug development services, providing the scientific insights and analytical scale necessary to advance precision medicine and clinical research.
Side-by-side fundamentals
| Metric | IQV | LH | Edge |
|---|---|---|---|
| Price as of 2026-07-30 close | $237.79 | $301.17 | |
| Market cap as of 2026-07-31 | $39.2B | $25.9B | |
| P/E as of 2026-07-31 | 29.48 | 27.48 | LH lower |
| PEG as of 2026-07-31 | 1.83 | 2.76 | IQV lower |
| Net margin as of 2026-07-31 | +8.1% | +6.7% | IQV higher |
| Gross margin as of 2026-07-31 | +33.0% | +28.8% | IQV higher |
| Operating margin as of 2026-07-31 | +12.9% | +10.2% | IQV higher |
| ROE as of 2026-07-31 | +21.9% | +10.9% | IQV higher |
| ROA as of 2026-07-31 | +4.7% | +5.1% | LH higher |
| Debt / equity as of 2026-07-31 | 2.59 | 0.73 | LH lower |
| Revenue growth (YoY) as of 2026-07-31 | +8.2% | +7.3% | IQV higher |
| Revenue CAGR (3y) SEC XBRL | +4.2% | +5.6% | LH higher |
| Dividend yield as of 2026-07-31 | n/a | +0.9% | |
| Dividend streak (yrs) SEC XBRL | 1 | 4 | LH higher |
| Beta as of 2026-07-31 | 1.01 | 0.85 | |
| 1-year return as of 2026-07-30 close | +24.1% | +13.7% | IQV higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.